· 

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in phase III TOSCA trial in high-risk colon cancer patients

Annamaria Ruzzo, Francesco Graziano, Fabio Galli, Elisa Giacomini, Irene Floriani, Francesca Galli, Eliana Rulli, Sara Lonardi, Monica Ronzoni, Bruno Massidda, Vittorina Zagonel, Nicoletta Pella, Claudia Mucciarini, Roberto Labianca, Maria Teresa Ionta, Enzo Veltri,Pietro Sozzi, Sandro Barni, Vincenzo Ricci, Luisa Fortran, Mario Nicolini, Edoardo Biondi, Annalisa Bramati, Daniele Turci, Silvia Lazzarelli, Claudio Verusio, Francesca Bergamo, Alberto Sobrero, Luciano Frontini, &Mauro Magnani.

Scientific Reports \ 4 : 6828 \ DOI: 10.1038/srep06828

· 

The IDEA Collaboration

Curr Colorectal Cancer Rep (2013) 9:261-269

Thierry André & Timothy Iverson & Roberto Labianca & Jeffrey A. Meyerhardt & Ioannis Souglakos & Takayuki Yoshino, & James Paul & Alberto Sobrero, & Julien Taieb & for the IDEA Steering Committee

· 

Enrico Aitini, Giancarlo Martignoni, Roberto Labianca, and on behalf of the Italian Group for the Study of Digestive Cancer (GISCAD)

Communication Models for Doctor-Patient Relationship

Journal of Cancer Educatio 10.1007/s13187-014-0616-z

Stefano Cascinu, Rossana Berardi, Alberto Sobrero, Paolo Bidoli, Roberto Labianca, Salvatore Siena, Daris Ferrari, Sandro Barni, Enrico Abitini, Vittorina Zagonel, Francesco Caprioni, Federica Villa, Stefania Mosconi, Luca Faloppi, Giuseppe Tonini, Corrado, Boni, Piefranco Conte, Francesco Di Costanzo, Michela Cinquini, on behalf of the Italian Group for the Study of Digestive tract Cancer (GISCAD)

Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: a GISCAD randomized phase II study

Dig Liver Dis. 2014 Feb; 46(2):182-6. doi: 10.1016/j.dld.2013.09.020. Epub 2013 Nov 2.

Cancer Cheater Pharmacy - Published Online: 11 May 2012 - DOI 10.1007/S00-280-012-1875-1

· 

Alberto Zaniboni, Enrico Abitini, Sandro Barni, Daris Ferrari, Stefano Cascinu, Vincenzo Catalano, Giuseppe Valmadre, Domenica Ferrara, Enzo Veltri, Claudio Codignola and Roberto Labianca for the GISCAD (Italian Group for the Study of Gastrointestinal Cancer)

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multi center phase II study

· 

Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicolella D, Aglietta, Lonardi S, Corsi D, Turci D, Beretta GD, Formarini G, Dapretto E, Floriani I, Zaniboni A, on behalf of Italian Gourp of the Study of Gastrointestinal Cancer - GISCAD

Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomized "Giscad" trial